000			03471nam a22005415i 4500
001			978-3-540-45567-7
003			DE-He213
005			20161121230958.0
007			cr nn 008mamaa
008			100301s2007 gw | s |||| 0|eng d
020			_a9783540455677 _9978-3-540-45567-7
024	7		_a10.1007/978-3-540-45567-7 _2doi
050		4	_aHG1-HG9999
072		7	_aKFF _2bicssc
072		7	_aBUS027000 _2bisacsh
082	0	4	_a332 _223
100	1		_aBogdan, Boris. _eauthor.
245	1	0	_aValuation in Life Sciences _h[electronic resource] : _bA Practical Guide / _cby Boris Bogdan, Ralph Villiger.
264		1	_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg, _c2007.
300			_aXII, 249 p. 94 illus. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aIntroduction -- Fundamentals in Life Sciences -- Basics of Valuation -- Project Valuation -- License Contract Valuation -- Technology Valuation -- IP Valuation -- Firm Valuation -- Advanced Topics -- Valuation and Gut Feeling -- Excercises.
520			_aCapital, whether it originates from venture, public equity, private, or g- ernment sources, continues to be biotech’s source of sustenance. In fact, access to financing can make or break a company, regardless of whether it has Nobel Prize winning science or a top-flight business school mana- ment team. In order to attract capital there has to be a “value proposition” that is sufficiently engaging and well constructed that will not only capture the imagination of investors but also make them want to ultimately invest. This book recognizes that there is no consent on how to apply valuation methodologies in life sciences. One of the complicating factors is that, compared to other industries, valuation of biotech innovation is much more demanding. The long 10-15-year development and clinical trials process still represents the main risks faced by any biotech company. Added to that is the fact that getting a drug across the regulatory goal line and receiving Food and Drug Administration approval (or other regulatory agency - proval in the United States or elsewhere in the world) for marketing is no longer good enough. Since the biotechnology industry is not isolated from the major influences affecting the overall healthcare industry, the reality of de facto healthcare cost controls will mean a significant reduction in “peak sales” for individual drugs. Science will no longer be the deciding factor; payor agents will play a far more activist role via reimbursement criteria, co-payment arrangements and similar rationing technologies.
650		0	_aFinance.
650		0	_aPharmacy.
650		0	_aManagement.
650		0	_aBiotechnology.
650		0	_aHealth informatics.
650		0	_aBioinformatics.
650		0	_aComputational biology.
650	1	4	_aFinance.
650	2	4	_aFinance, general.
650	2	4	_aComputer Appl. in Life Sciences.
650	2	4	_aHealth Informatics.
650	2	4	_aPharmacy.
650	2	4	_aBiotechnology.
650	2	4	_aManagement.
700	1		_aVilliger, Ralph. _eauthor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783540455653
856	4	0	_uhttp://dx.doi.org/10.1007/978-3-540-45567-7
912			_aZDB-2-SBE
950			_aBusiness and Economics (Springer-11643)
999			_c506761 _d506761